RECONSIDERING ONCOLOGY TODAY - QUO VADIS ONCOLOGIA?
Abstract
No AbstractReferences
ANONYMOUS: Breast Cancer: have we lost οur way? Lancet 1993; 341: 343-344
BAILAR J.C., SMITH R.M.: Ηaνe we reduced the risk οf getting cancer οr of dying from cancer? Αn update. Med. Oncol. Tumor Pharmacother. 1987; 4: 193-198
VAN DER MERWE C.F.: The reversibility of cancer, 10 years on. SAMJ 1993; 83: 69
MANOLAKIS G.: Σύγχρονες απόψεις για την αντιμετώπιση των συμπαγών νεοπλασιών. 3ο Διαπανεπιστημιακό Ακτινολογικό και Ογκολογικό Συνέδριο. Αλεξανδρούπολη 5-7 Νοεμβρίου 1993
DeVITA V., HELLMAN S., ROSENBERG S.: Cancer - Principles & Practice of Oncology. 4th Edition, J.B.Lippincott Co. 1993
HOLLAND J. ΕΤ AL: Cancer medicine 3rd Edition, Lea & Fabiger 1993
MANOLAKIS G.: The therapeutic role of ΕΡΟ in the treatment of otherwise untreatable gastrointestinal tract malignancies. Ph .D. - Dissertation in Oncology, Medical University of Sοuthern Africa - MEDUNSA - 1994
FURTH J., KALIM M.C.: The transmission of leukemia οf mice with a single cell. Am. J. Cancer 1937; 31: 276-282
SCHIPPER Η., GOH C., WANG Τ.: Rethinking Cancer: should we control rather than kill? Part Ι Can. J. Oncol. 1993; 3(3): 207-216, Part 2 Can. J. Oncol. 1993; 3(3): 220-224
McGRATH M.S., SHIRAMIZU Β., ΕΤ AL: AIDS associated polyclonal lymphoma. Identification οf a new HIV-associated disease process. J. Acq. Imm. Def. Syndr. 1991; 4: 408-415
LIST A.F., GRECO F.Α., ΕΤ AL: Lymphoproliferative disease in immunocompromised hosts: The role of Epstein - Βarr νiruus. J. Clin. Oncol. 1987; 5: 1673-1689
KRUEGER G.R., PAPADAKIS Τ., ΕΤ AL: Persistent active Epstein - Βarr virus infection and atypical lymphoproliferation. Report on 2 cases. Am. J. Surg. Pathol. 1987; 11: 972-981
GORDON-SMITH E.C.: Non-malignant clonal disorders. Semin. Hematol. 1989; 26: 175-245
HENDERSON l.C.: Biologic variations of tumors. Cancer 1992; 69: 1888-1895
SONTA S., SANDBERG Α.Α.: Cromosomal causation of human cancer and leukemia ΧΙΧΧ. Further studies on karyotype progression in CML. Cancer 1978; 41: 153
SCHIPPER Η., BOW Ε. ΕΤ AL: Coexistence of double gammoρathy (lgM Kappa and lgM Lambda) in the serum οf a single individual with chronic lymphocytic leukemia. ACTA Haem. 1983; 69: 23-31
FIDLER I.J., HART I.R.: Biologic diversity in metastatic neoplasms-origins and implications. Science 1982; 217: 998- 1001
FIΊDLER I.J.: 7th Jan Waldenstroem Lecture. The biology of human cancer metastasis. ACTA Oncol. 1991; 30: 668-675
COLLARD J.G., VAN DER POL Μ., ΕΤ AL: Location of genes involved in invasion and metastasis on human chromosome 7. Cancer Res. 1987; 47: 6666-6670
LIOTTA L.A., STEEG P.S., ΕΤ AL: Cancer metastasis and angiogenesis: Αn imbalance of positive and negative regulation. Cell 1991; 64(2): 327-336
DOLNICK B.J., ΕΤ AL: Correlation of dihydrofolate reductase elevation with gene amplification in a homogeneously staining chromosomal region in L5178Υ cells. J. Cell Βίοl. 1979; 83: 399-402
FΌJO Α.Τ., UEDA Κ., ΕΤ AL: Expression of a multi-drug resistance gene in human tumors and tissues. Ρrοc. Natl. Acad. Sci. USA 1987; 84: 265-269
MEIJIER C., MULDER Ν.Η., ΕΤ AL: The role of detoxifying systems in resistance of tumor cell to cisplatin and adriamycin. Cancer Treat. Rev. 1990; 17 (4): 389-407
JUDSON I.R.: Understanding anticancer drug resistance: Opportunities for modulation and impact on new drug design. Εur. J. Cancer 1992; 28: 285-289
URBA W.J., LONGO D.L.: Cytologic, immunologic and clinical diνersity in Non-Hodgkins lymphoma : theraupetic implications. Semin. Oncol. 1985; 12:250-267
FLETCHER R.H.: Carcinoembryonic antigen. Ann. Intern Med. 1986; 104: 66-73
KARLSSON I., ΕΤ AL: Τurnονer in humans οf b2 microglobulin. Eur. J. Clin. Inv. 1980; 10: 293-300
FΊALKOW P.J.: The origin and development οf human tumours studied with cell markers. N. Engl. J. Med. 1974; 291: 261
FEIZI T.: Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nat. 19885; 314: 53-57
BATES S.E.: Clinical applications of serum tumor markers. Ann. Intern. Med. 1991; 115: 623-638
AARONSON S.A.: Growth factors and cancer. Science 1991; 254: 1146-1153
COLD SPRING HARBOUR LABORATORY: Oncogenes and the molecular origins of cancer. 1989
LEUTZ Α., GRAF Τ.: Relationships between oncogenes and growth control. In Sporn Μ.Β., Roberts Α.Β., editors, Peptide Growth Factors and their Receptors, Heidelberg , Springer Verlag 1991; 655-703
HIRAΥΑΜΑ R., SAWΑΙ S., ΕΤ AL: Positive relationship between expression of anti-metastatic factor (nm 23 gene product οr nucleotiside diphosphate kinase) and good prognosis in human breast cancer. J. Natl. Cancer Inst. 1991; 83: 1249-1250
STEEG P.S., COHN Κ.Η., ΕΤ AL: Τumοr metastasis and nm 23: Current concepts. Cancer Cells 1991; 3: 257-262
SPORN Μ.Β., ROBERTS A.Β.: Aurocrine secretion - 10 years later 1992; 117: 408-414
SPORN Μ.Β., ROBERTS Α.B.: Peptide growth factors are multifunctional. Nature 1988; 332: 217-219
ROUSLAHTI Ε.: Control οf cell motility and tumour invasion by extracellular matrix interactions. Br. J. Cancer 1992; 66: 239-242
TROSKO J.E., JONE C., ΕΤ AL: Inhibition of gap junctional - mediated intercellular communication in vitro by aldrin, dieldrin and toxaphene: a posible cellular mechanism for their tumor - promoting and neurotoxic events. Molecular Toxicology 1987; 1: 83-93
TROSKO J.E.: Mechanisms of tumor promotion: Possible role of inhibited intercellular communication. Eur. J. Cancer Clin. Oncol. 1987; 23: 599-601
WHITMORE W.F. JR: The natural history of prostatic cancer. Cancer 1973; 32: 1104-1112
NIELSEN Μ., JENSEN J. ΕΤ AL: Precancerous and cancerous breast lesions during lifetime and at autopsy. Cancer 1984; 54: 612-615
FISHER Β., MONTAGUE Ε., ΕΤ AL: Comparison of radical mastectomy with alternative treatment for primary breast cancer: a first report of result s from a prospective triial. Cancer 1977; 39: 2827-2834
DeWYS W.D.: Studies correlating the growth rate of a tumor and its metastases and providing evidence of tumor-related systemic growth-retarding factors. Cancer Res. 1972; 32: 374-379
FISHER Β., GUNDUZ Ν. ΕΤ AL: lnfluence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastasis. Cancer Res. 1983: 43: 1488-1492
FISHER Β., SAFFER Ε.Α., ΕΤ AL: Influence of irradiation οf a primary tumor on the labelling index and estrogen receptor index in a distant tumor focus. Ιnt. J. Radiat Oncol. Βίοl. Phys. 1986: 12: 879-885
NORTON L.: Biology οf residual breast cancer after therapy: a kinetic interpretation Prog. Clin. Biol. Res. 1990: 354Α: 109-132
ROGE J., DRUET Ρ., ΕΤ AL: Alpha chain disease: cured with antibiotics (letter) Βr. Med. J. 1975; 4: 225
BASSET Ρ., BELLOCQ J.P., ΕΤ AL: Α novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699-704
ALCALAΥ Μ., ZANGRILLI D., ΕΤ AL: Translocation break poinr of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Ρroc. Natl. Acad. Sci. USA 1991; 88: 1977-1981
HUANG Η., ΥΕ Υ., ΕΤ AL: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572
WARRELL R.P.JR.: All-trans retinoic acid. What is good for? J. Clin. Oncol. 1992; 10: 1657-1661
KAPOOR Ν., COPELAN Ε.Α., ΕΤ AL: Graft-versus-host disease. Effects on long term disease-free survival in marrow transplantation for haematological malignancies. Bone Marrow Transpl. 1989; 4 (Suppl. 4): 153-155
SULLIVAN Κ.Μ., FEFER Α., ΕΤ AL: Graft-versus-leukemia in man: Relationship of acute and chronic graft-νersus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. Ρrog. Clin. Βίοl. Res. 1987; 244: 391-399
BRAMBILLA Ε., MORO D., ΕΤ AL: Cytotoxic chemotherapy induces cell differentiation in small-cell lung cancers. J. Clin. Oncol. 1991; 9: 50-61
FOA R., GUARINI Α., ΕΤ AL: IL2 treatment for cancer: from biology to gene therapy. Βr. J. Cancer 1992; 66: 992-998
BILLARD C., SIGAUX F., ΕΤ AL: Treatment οf hairy cell leukemia with recombinant Alpha interferon: In vivο down-regulation of Alpha interferon receptors on tumor cells. Blood 1986; 67: 821-826
QUESADA J.R., HERSCH Ε.Μ., ΕΤ AL: Treatment of hairγ cell leukemia with recombinant alpha-interferon. Blood 1986; 68: 493-497
EARLΥ BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Systemic trearment of early breast cancer by hormonal, cytotoxic, οr immune therapy. 133 randomised trials involving 31.000 recurrences and 24.000 deaths among 75.000 women. Lancet 1992; 339: 1-15
FISHER Β., REDMOND C., ΕΤ AL: Α randomized clinical trial evaluating sequential merhotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumοrs. Ν. Engl. J. Med. 1989; 320: 473-478
GUBNER R., AUGUST S., ΕΤ AL: Theraupeutic suppression οf tissue reactivity. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am. J. Med. Sci. 1951; 221: 176-182
WEINBLATT Μ.Ε. , COBLΥΝ J.S., ΕΤ AL: Efficacy of low-dose methotrexate in rheumatoid arthritis. Ν. Engl. J. Med. 1985; 312: 818-822
RABKIN C.S., BIGGAR R.J., ΕΤ AL: Increasing incidence of cancers associated with the human immunodefficiency νirus epidemic. Int. J. Cancer 1991; 47: 692-696
SKIPPER Η.Ε.: Historic milestones in cancer biology: a few that are important in cancer treatment. Semin. Oncol. 1979; 6: 506-514
SKIPPER Η.Ε., PERRY S.: Kiπetics οf normal and leukemic leucocyte populations and relevance to chemotherapy. Cancer Res. 1970; 30: 1983
